Searched for
KYOWA PHARMACEUTICALS INDUSTRY
Japan shares hit 5-week high on vaccine, economic growth hopesThe Nikkei index settled 1.59% higher at 22,945.50 after hitting its highest level since June 10, with industrial and consumer discretional...- Japan stocks rise by most in one month, caution about virus remainsThe Nikkei index ended 1.09 per cent higher at 21,329.12.
- Lupin to divest entire stake in Kyowa for Rs 3,702 croreThe deal proceeds will be utilised to strengthen company's balance sheet.
- Lupin looks to sell Japanese arm Kyowa for $600 millionKyowa grew a modest 5% over the year-ago level. Its net profit halved to Rs 68.6 crore constituting 11.3% of Lupin’s consolidated profit. "...
- Lupin arm in pact to distribute anti-depressant drug in JapanLupin President Dr. Fabrice Egros said the Astellas agreement reinforces Kyowa's transition toward a hybrid pharmaceutical specialty care c...
- Lupin arm buys branded drugs from Japan’s ShionogiThe new branded product portfolio has a strong fit with Lupin’s Kyowa business, as it adds depth and reach to its current CNS (central nerv...
- Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brandsThe acquisition will result in a wider offering for Lupin in Japanese market where its sales last fiscal stood at Rs 1,364 crore.
- Mumbai-based Lupin looks at buyouts in Japan after Sun Pharmaceutical’s entryWith the Japanese government pushing for generic prescription, Lupin is among the companies hunting for acquisitions in a country that is e...
- Lupin's subsidiary Kyowa to set up plant in JapanKyowa Pharmaceutical Industry Co is a wholly-owned subsidiary of the the Mumbai-based firm. It has a manufacturing facility at Sanda, Japan.
- Lupin identifies cancer drugs as focus area in JapanLupin has identified cancer drugs as the new focus area in the Japanese market where patents on products worth $ 2 billion are expected to ...
- Lupin aims to double sales in Japan to $500 million in next 5 yearsDrug firm Lupin is targeting to double sales in Japan to $500 million (over Rs 2,600 crore) in the next five years on the back of enhanced ...
- Lupin eyes USD 300 mn revenues from Japan in next 2 yearsDrug maker Lupin is eyeing a jump of over 80 per cent in its revenues to $300 million (about Rs 1,557 crore) from the Japanese market in th...
- Lupin expects to launch 50 products globally in FY12Drug maker Lupin expects to launch nearly 50 products in the current fiscal in various markets across the globe, including up to 12 product...
- Lupin targets buys in Gulf, Mexico, Brazil and ArgentinaLupin Ltd. continues its buying spree with planned acquisitions in Gulf, Mexico, Brazil and Argentina.
- Lupin's Japanese arm gets nod to sell 10 productsThe company plans to launch these products by July 2008. Lupin is the first Indian co to get approval from the Japanese drug authorities to...
- Lupin's Japanese arm gets nod for 10 productsLupin's Japanese subsidiary Kyowa Pharma has received approvals for 10 products and expects to launch these in July 2008 post NHI listing.
- Lupin to shift Japanese arm’s manufacturing to IndiaIn a bid to improve the profitability of its Japanese venture Kyowa Pharmaceutical Industry, Indian drug maker Lupin is planning to bring t...
- Dr Reddy's looks for partner to enter Japanese mktDr Reddy’s Laboratories is finalising plans to enter the Japanese market, the world’s second largest pharmaceutical market.
- Dr Reddy's scouts for partner to enter Japanese marketThe Hyderabad-based company is looking for a partner to launch its products in Japan by next fiscal year. Smart ways to invest or spend!
- Lupin makes a leap into Japanese pharma marketLupin’s acquisition in Japan gives it a foothold in a large pharmaceutical market with relatively low generic penetration. Japan is the wor...
Load More
